show episodes
 
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO with episodes launching weekly on Tuesday's. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials
  continue reading
 
Artwork
 
Mo Mandel (Chelsea Lately, Comedy Knockout, CONAN) goes through the most challenging and divisive issues of the day with a rotating pool of guests. He also complains a lot about his own life.
  continue reading
 
This is the official PodCast of the Big Box PC Game Collectors group. We are a group who focuses on PC game collecting, and we cover all personal computers including the Apple II, Commodore, TRS-80. We're not limited to vintage PC games; we even cover modern big box PC releases.
  continue reading
 
Artwork
 
A podcast discussing backlist gems and the Spanish writer Javier Marías, late the King of Redonda. In Season 2 we read the novels of Muriel Spark. From Lori Feathers and Tom Flynn.
  continue reading
 
Loading …
show series
 
We’re joined today by Josh Cook. Josh is a bookseller and co-owner at Porter Square Books in Cambridge, Massachusetts, where he has worked since 2004. He is the author of the critically acclaimed postmodern detective novel An Exaggerated Murder and most recently of The Art of Libromancy: Selling Books and Reading Books in the Twenty-First Century, …
  continue reading
 
Explore the untapped potential of RNA amplifying therapeutics with the CEO of CAMP4 Therapeutics, Josh Mandel-Brehm. We uncover the power of antisense oligonucleotides in rewriting the narrative for genetic diseases characterized by protein deficiency. Josh takes us behind the scenes of their innovative RNA Actuating Platform (RAP), a map charting …
  continue reading
 
Embark on a journey through the neurons and synapses of brain science with William Korinek, the CEO of Astrocyte Pharmaceuticals. In a conversation that fuses the molecular intricacies of neuroprotection with the humanistic pursuit of medical advancement, Bill reveals his unique path from molecular biologist to biotech innovator. Together, we unrav…
  continue reading
 
We’re joined today by Lara Ehrlich, a writer, editor, and longtime friend (she and Tom go back 20 years, which seems impossible). Her first story collection, Animal Wife, was published by Red Hen Press back in 2020, and her first novel, Bind Me Tighter Still, will publish in 2025, also from Red Hen. She also hosts a conversation series, Writer Moth…
  continue reading
 
Join as we dive deep into the world of oncology drug development with Bas van der Baan of Lixte. Discover the inspiration behind Lixte's focus on PP2A inhibitors and how this innovative approach is poised to revolutionize cancer treatment by enhancing chemotherapy and immunotherapy responses. Bas shares insights into ongoing clinical trials, regula…
  continue reading
 
We’re joined today by Mark Haber of Coffee House Press (formerly of Brazos Bookstore in Houston). Mark is the author of two novels, Reinhardt’s Garden and Saint Sebastian’s Abyss, and the forthcoming novel Lesser Ruins, as well as a forthcoming novella, Ada. We chat about his work as well as Austerlitz by W.G. Sebald, translated by Anthea Bell. A q…
  continue reading
 
Dr. Samar Mohanty, president and CSO of Nanoscope Therapeutics joins us to shed light on the revolutionary gene therapy that's giving hope to individuals with retinal degenerative diseases by pioneering a treatment that can re-sensitize the retina to detect low light levels. We open the curtains on their groundbreaking multi-characteristic opsins (…
  continue reading
 
Today Spencer Ruchti of Third Place Books joins to chat about The Tanners by Robert Walser, translated by Susan Bernofsky. We actually recorded this back in November and are glad to get it out into the world. Early on Spencer dips out momentarily due to an alarm in the store, but all ended up being right with the world. At least in that instant. Th…
  continue reading
 
Imagine unlocking the secrets to revitalizing the brain's energy centers and turning the tide on neurodegenerative diseases. In this episode, Rob introduces us to CNM-Au8, an oral nanotherapeutic with the potential to recharge failing mitochondria. Our discussion traverses the innovative path Clene has charted, from the drug's conception to the exc…
  continue reading
 
Kicking off 2024 we welcome Tara Cheesman to the podcast with her recommendation, Being Here Is Everything: The Life and Times of Paula Modersohn-Becker by Marie Darriussecq, translated by Penny Hueston. Tara is a freelance critic, former judge of the Best Translated Book Award, and she brings us our first work of nonfiction. We have an absolutely …
  continue reading
 
Step into the future as Dr. Jason Bock, founder and CEO of CTMC discusses the company's unique approach to accelerating cell therapies from development to testing, and the power of collaboration in reshaping the future of cancer treatment. Listen in as we discuss how CTMC's partnership with MD Anderson is not just technical but deeply human in natu…
  continue reading
 
Embark on a quest to unravel the 'undruggable' genome with Alex Federation, Co-founder of Talus Bio. Explore challenges in targeting transcription factors in cancer with Talus's innovative Marmot platform. Discover potential breakthroughs in rare diseases and pediatric cancers, and glimpse into the future of studying transcription factors within li…
  continue reading
 
Join Dr. Ahmed Hamdy, CEO of Vincerx Pharma, on a compelling journey through oncology. From co-founding Acerta Pharma to pioneering patient-centric innovations, Dr. Hamdy shares his impactful career. Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical ex…
  continue reading
 
Have you ever considered the untapped potential of abandoned drugs? Join Dr. Sam Clark to discuss how his personal drive to combat mental illness is leading to breakthroughs in treatments for neurological and psychiatric diseases. Witness how Terran is not only resurrecting discarded medications for new purposes, but also pioneering the next genera…
  continue reading
 
Ever wondered how technology could drastically improve early detection in healthcare? Let us take you on a journey with Mark McDonough, President and CEO of ChromaCode, as we unfold the world of molecular diagnostics with a special focus on HDPCR technology. Mark, with his diverse background in the military and healthcare, brings a fresh perspectiv…
  continue reading
 
Embark on a journey through the intricate world of biotech with Bogdan Kezevic, co-founder and CEO of Kaleidoscope Bio, and uncover the revolutionary software shaping the future of scientific research. Bogdan's leap from scientist to entrepreneur has led to groundbreaking solutions for the challenges plaguing biotech. In our chat, he shares how dat…
  continue reading
 
What does it take to revolutionize the world of vaccines and touch lives across the globe? Join us on a riveting journey with Steven Reed, CEO and co-founder of HDT-Bio, as we explore the creation of the first refined tuberculosis vaccine and dive into the remarkable strides in RNA technology. This episode lifts the veil on the science that could r…
  continue reading
 
The Prime of Miss Jean Brodie is upon us and it does not disappoint. Too much to say about this one and, as always, we could have gone an hour longer and still not covered it all. An absolutely fantastic novel and one that certainly lives up to the hype and praise that surrounds it. Titles/authors mentioned: The Secret History by Donna Tartt O Cale…
  continue reading
 
We stand on the precipice, one episode away from THE PRIME! Before that, though, we discuss The Bachelors, a fantastic novel chock full of some of the strangest characters Spark has written, which is really saying something. Mediums, epileptics, blackmail, criminality, and much, much more abound in this one. And one of the funniest scenes yet invol…
  continue reading
 
Join Jeffrey Bacha, a pioneer in the fight against cancer and the creative force behind Rakovina Therapeutics. For 25 years, Jeffrey has been reshaping the industry landscape, and today, he gives us a peek into his world of innovation. We venture into Rakovina's research and development of oncology drugs. exploring their groundbreaking technique co…
  continue reading
 
We’re edging closer to THE PRIME, but today we chat about The Ballad of Peckham Rye. Spark’s novels are incredibly fun, but this might be the wildest, featuring an incredible character name (Dougal Douglas), a lot of absenteeism, a textile factory, a Nun Tunnel, and dancing. Lots of dancing. Click here to subscribe to our Substack and find us on th…
  continue reading
 
Embark on a fascinating exploration of biotech entrepreneurship, guided by an expert who's been in the trenches: Jonathan Thon, CEO and founder of STRM.BIO. We'll give you an insider's view of his journey from academia to the cutting edge of biotech, unveiling his trailblazing work on platelet production and the transformative potential of extracel…
  continue reading
 
Ever wondered how far we've truly come in the realm of gene and cell therapies, and where we're headed next? This captivating conversation with Oscar Segurado, the CMO of ASC Therapeutics, will satisfy your curiosity. Oscar, a veteran in the biopharmaceutical industry, shares fascinating insights on ASC Therapeutics' groundbreaking innovation in pe…
  continue reading
 
This week we discuss Tell Them of Battles, Kings, and Elephants, an absolutely wonderful gem of a novel from French author Mathias Énard, translated by Charlotte Mandell. In 150ish pages Énard recreates the Constantinople of the early 16th Century and the brief time Michelangelo resided there to build a grand bridge. If you’ve not read Énard before…
  continue reading
 
We’re thrilled to share our enlightening exchange with Spiro Rombotis, the seasoned CEO of Cyclacel. He peels back the curtain on the breakthrough discovery of B53, a commonly mutated gene in cancer patients, and the inspiring success of FADRA, their lead drug in clinical trials. Furthermore, Spiro delves into the highs and lows faced by Cyclacel, …
  continue reading
 
This week we discuss Memento Mori, Spark’s third novel and, as we’ve come to expect, it’s a really fun ride. This go-round she brings us into the lives of septuagenarians and octogenarians as they fume, backbite, explore their sexual proclivities, and all come to terms (or not) with their impending deaths. And, of course, it’s very, very funny. Cli…
  continue reading
 
Episode 5 of Season 2: we get to chat with Robin McLean about Ceremony by Leslie Marion Silko. And, yeah, this is probably our best episode so far, which isn’t shocking because we’re talking about talking with Robin McLean. So, all that aside, it’s a great conversation and one that could have gone on for hours and hours yet. We could have gone deep…
  continue reading
 
In Episode 4 of Season 2 we dig into Muriel Spark’s sophomore effort, Robinson. Gotta say: it’s incredible and we couldn’t be more excited to keep on keeping on with her work. This time around we trade London (mostly) for a lonely island in the Atlantic and a story that is funny, tense, clever, whimsical, and just an all-around masterclass in write…
  continue reading
 
Ever wondered about the people who are leading the fight against cancer, developing groundbreaking treatments, and changing lives? Meet Frank Boriello, the mind behind SUPLEXA cell therapy, and the CEO and founder of Alloplex Biotherapeutics. In our conversation, Frank shares the personal backstory that sparked his quest to revolutionize cancer tre…
  continue reading
 
Having sorted some annoying technical issues, herewith Episode 3 of Season 2 (our way of apologizing for the delay in uploading this episode) in which we discuss The Conqueror by Jan Kjærstad, translated by Barbara Haveland and published by Open Letter Books. And to kick off our series of guest hosts, Chad Post of Open Letter Books (and Dalkey Arch…
  continue reading
 
Max Darnell, CEO and co-founder of Modulus Therapeutics, takes us through his thrilling journey from bioengineering and systems biology to launching a biotech startup. Max unveils how his team's curiosity and motivation, along with their high throughput discovery platform, are revolutionizing cell and cell therapy component designs. Hear how Modulu…
  continue reading
 
We kick off our season-long read of Muriel Spark's novels this week and what a start! The Comforters is Spark's debut, published in 1956, and is, quite simply, magnificent. Lori and Tom wax heavily on how impressive this novel is and how incredibly fun it is, too! It's going to be quite a great season judging by this title alone. Click here to subs…
  continue reading
 
Join 30-year industry veteran Pepper Landson, Co-founder and CEO of Praetego as she shares her inspiring journey that led her to tackle Alzheimer's and dementia through the innovative use of amadorins. Pepper's intriguing narrative not only highlights her commitment to the public health crisis surrounding these neurodegenerative diseases, but also …
  continue reading
 
And we’re back! Welcome to Season Two of Lost in Redonda. We kick things off with a backlist conversation on Chronicle of the Murdered House by Lucio Cardoso, translated by Margaret Jull Costa and Robin Patterson, published by Open Letter Books. It’s probably one of the fastest moving 600 page sagas of a Brazilian family you’re likely to encounter.…
  continue reading
 
Ever wonder how the complexities of gene therapies are addressed from bench to bedside? The creative solutions lie within the innovative approaches of seasoned professionals like Dr. Timothy Miller, Co-Founder, President, & CEO at Forge Biologics. With a fascinating career that interlaces academia, biotech, and entrepreneurship, Dr. Miller brings a…
  continue reading
 
What if your vision could be saved by the precise application of innovative biotech? Join us as we talk to David Esposito, President & CEO of ONL Therapeutics, and delve deep into his take on leadership. He shares how his military background has been instrumental in the successful management of clinical trials, particularly when navigating the unpr…
  continue reading
 
Does the convergence of tech and biology hold the key to reshaping biotech's data infrastructure? Our recent chat with Alfredo Andere, Co-Founder and CEO at LatchBio, certainly supports this notion. This episode offers a deep dive into Alfredo's journey from being part of the Google Brain team to co-founding Latch Bio - a company that is making wav…
  continue reading
 
Here it is, folks, our final episode on Your Face Tomorrow and the last part of our Marías project. It's a longer one, but very worth it if we do say so ourselves. Our next season and new project will kick off in a couple weeks' time, but before that a thank you for listening along. It's a fun project and one we hope folks are getting as much out o…
  continue reading
 
Embark on a journey into the forefront of biotech with Lucas Siow, the visionary behind ProteinQure, as he unveils the impact of his computational platform on peptide therapeutics and delves into the art of team building. Explore the fusion of medicinal chemistry and high throughput screens, discover the essence of benchmarking in drug discovery, a…
  continue reading
 
It's very strange to be this close to the end of our Marías focus, but that's rather how time moves, ever forward (unless you're Marías and can make time a rather fungible thing in your novels...). This is a fun episode, touching on East End gangsters, Spandau Ballet, the Spanish Civil War, swordplay, and more. And a couple of characters from the p…
  continue reading
 
And now we enter the homestretch. Over the next few episodes we'll tackle Marías' masterpiece, Your Face Tomorrow. Starting, of course, with the first volume, Fever and Spear. Once we wrap up the Marías project we're going to take a week or so off and then we'll be back with more backlist dives and a new author whose work we'll spend some time digg…
  continue reading
 
This week we dive into Christian Kracht's Imperium, and boy do we ever go deep (sorry/not sorry). It's an incredible piece of historical fiction (one of Tom's favorites and, now, one of Lori's) that follows one man's attempts to manifest his destiny to live in the tropics and subsist only on the noble coconut. And walk around nude. In the German So…
  continue reading
 
A fun discussion this week of two novels published almost 30 years apart in The Infatuations and The Man of Feeling. We walk down some interesting paths and may get ourselves into a moral quandary or two (wouldn't be a discussion of Marías without some moral murkiness, now would it?). These are the last two Marías novels we discuss before wrapping …
  continue reading
 
We're going weekly! As the episodes have grown longer we've decided to split them up so instead of discussing two titles per episode (and delivering a 2+ hour podcast) every other week we're switching to one title every week. A guide to the next few episodes will be up on the Substack shortly. This week we dig into Marie NDiaye's My Heart Hemmed In…
  continue reading
 
In our sixth episode we discuss Gob’s Grief by Chris Adrian for our backlist deep dive. In the Marías portion we dig into Thus Bad Begins (spoiler alert: it’s phenomenal). This is a doozy of an episode, so stay hydrated and do be a hero: listen to the whole 2+ hours in one go! Books mentioned in this episode: Names on the Land: A Historical Account…
  continue reading
 
For episode 38, we sit down with Stephen Doyle, Chief Business Officer at ASLAN Pharmaceuticals. Find out more about the challenges involved in developing innovative treatments and how ASLAN is addressing those difficulties as they work to bring new therapies like their novel atopic dermatitis treatment to the market. First In Human is a biotech-fo…
  continue reading
 
For episode 37, we connect with David Bearss, President and CEO of Halia Therapeutics. Learn more about the connection between chronic inflammation and disease, and how Halia is using their novel therapies to treat both inflammatory disorders and neurological diseases. First In Human is a biotech-focused podcast that interviews industry leaders and…
  continue reading
 
Lori and Tom discuss Marías' final novel, Tomás Nevinson, just published in the US on May 23rd. A warning that spoilers do occur, especially after the 37 minute mark, so listener beware. Next episode we will return to discussing backlist in addition to our Marías deep-dives. Click here to subscribe to our Substack and do follow us on the socials, @…
  continue reading
 
For Episode 36, we chat with Romain Micol, CEO & Co-Founder of Combined Therapeutics. Stay tuned to learn how Combined Therapeutics is developing unique mRNA-based treatments to better protect the world from infectious disease and cancer. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their…
  continue reading
 
Loading …

Quick Reference Guide